The Journal of Immunology, Vol 158, Issue 2 851-858, Copyright © 1997 by American Association of Immunologists

ARTICLES

B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes

G Yang, MT Mizuno, KE Hellstrom and L Chen
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA.

Efficient T cell activation requires two synergistic but distinct signals derived from antigenic peptides presented by the MHC and from costimulatory molecules, particularly those belonging to the B7 family. Lack of B7-CD28 interaction may cause unresponsiveness of T cells to subsequent exposure to Ag. Nevertheless, immunization by some B7- tumors induces an antitumor immune response. We found that the immune response against two B7- tumors, the mouse P815 mastocytoma and the E7C3 melanoma, requires host-derived B7, since blockage of the B7-CD28 interaction facilitates tumor growth and eliminates an antitumor response. B7 costimulation is provided in the regional, tumor-draining lymph nodes for the induction of a primary CTL response against both B7+ tumor and B7- tumor. However, the induction of a CTL response to B7+ tumors and its clonal expansion may occur at tumor sites in addition to secondary lymphoid organs so as to generate more effective tumor immunity.

This article has been cited by other articles:

				M. R. Raspollini, F. Castiglione, D. Rossi Degl'Innocenti, G. Amunni, A. Villanucci, F. Garbini, G. Baroni, and G. L. Taddei Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma Ann. Onc., April 1, 2005; 16(4): 590 - 596. [Abstract] [Full Text] [PDF]

				X.-F. Bai, J. Bender, J. Liu, H. Zhang, Y. Wang, O. Li, P. Du, P. Zheng, and Y. Liu Local Costimulation Reinvigorates Tumor-Specific Cytolytic T Lymphocytes for Experimental Therapy in Mice with Large Tumor Burdens J. Immunol., October 1, 2001; 167(7): 3936 - 3943. [Abstract] [Full Text] [PDF]

				X.-F. Bai, J.-X. Gao, J. Liu, J. Wen, P. Zheng, and Y. Liu On the Site and Mode of Antigen Presentation for the Initiation of Clonal Expansion of CD8 T Cells Specific for a Natural Tumor Antigen Cancer Res., September 1, 2001; 61(18): 6860 - 6867. [Abstract] [Full Text] [PDF]

				I. Hellström, J. A. Ledbetter, N. Scholler, Y. Yang, Z. Ye, G. Goodman, J. Pullman, M. Hayden-Ledbetter, and K. E. Hellström CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer PNAS, May 18, 2001; (2001) 21557498. [Abstract] [Full Text]

				C. L. van Broekhoven, C. R. Parish, G. Vassiliou, and J. G. Altin Engrafting Costimulator Molecules onto Tumor Cell Surfaces with Chelator Lipids: A Potentially Convenient Approach in Cancer Vaccine Development J. Immunol., March 1, 2000; 164(5): 2433 - 2443. [Abstract] [Full Text] [PDF]

				G. Willimsky and T. Blankenstein Interleukin-7/B7.1-encoding Adenoviruses Induce Rejection of Transplanted but not Nontransplanted Tumors Cancer Res., February 1, 2000; 60(3): 685 - 692. [Abstract] [Full Text]

				J. T. Tan, J. K. Whitmire, R. Ahmed, T. C. Pearson, and C. P. Larsen 4-1BB Ligand, a Member of the TNF Family, Is Important for the Generation of Antiviral CD8 T Cell Responses J. Immunol., November 1, 1999; 163(9): 4859 - 4868. [Abstract] [Full Text] [PDF]

				K. Sturmhoefel, K. Lee, G. S. Gray, J. Thomas, R. Zollner, M. O'Toole, H. Swiniarski, A. Dorner, and S. F. Wolf Potent Activity of Soluble B7-IgG Fusion Proteins in Therapy of Established Tumors and as Vaccine Adjuvant Cancer Res., October 1, 1999; 59(19): 4964 - 4972. [Abstract] [Full Text] [PDF]

				R. N. L. Motte, A. H. Sharpe, J. A. Bluestone, and M. B. Mokyr Host B7-1 and B7-2 Costimulatory Molecules Contribute to the Eradication of B7-1-Transfected P815 Tumor Cells Via a CD8+ T Cell-Dependent Mechanism J. Immunol., April 15, 1999; 162(8): 4817 - 4823. [Abstract] [Full Text] [PDF]

				R. N. La Motte, A. H. Sharpe, J. A. Bluestone, and M. B. Mokyr Importance of B7-1-Expressing Host Antigen-Presenting Cells for the Eradication of B7-2 Transfected P815 Tumor Cells J. Immunol., December 15, 1998; 161(12): 6552 - 6558. [Abstract] [Full Text] [PDF]

				A. Nakajima, T. Kodama, S. Morimoto, M. Azuma, K. Takeda, H. Oshima, S.-i. Yoshino, H. Yagita, and K. Okumura Antitumor Effect of CD40 Ligand: Elicitation of Local and Systemic Antitumor Responses by IL-12 and B7 J. Immunol., August 15, 1998; 161(4): 1901 - 1907. [Abstract] [Full Text] [PDF]

				M. B. Mokyr, T. V. Kalinichenko, L. Gorelik, and J. A. Bluestone Importance of the B7-2 Molecule for Low Dose Melphalan-Induced Acquisition of Tumor-Eradicating Immunity by Mice Bearing a Large MOPC-315 Tumor J. Immunol., February 15, 1998; 160(4): 1866 - 1874. [Abstract] [Full Text] [PDF]

				T. D. Armstrong, V. K. Clements, and S. Ostrand-Rosenberg MHC Class II-Transfected Tumor Cells Directly Present Antigen to Tumor-Specific CD4+ T Lymphocytes1 J. Immunol., January 15, 1998; 160(2): 661 - 666. [Abstract] [Full Text] [PDF]

				I. Hellstrom, J. A. Ledbetter, N. Scholler, Y. Yang, Z. Ye, G. Goodman, J. Pullman, M. Hayden-Ledbetter, and K. E. Hellstrom CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer PNAS, June 5, 2001; 98(12): 6783 - 6788. [Abstract] [Full Text] [PDF]